Acute promyelocytic leukemia (APL), characterized by the PML-RARA fusion oncogene [1], represents 5–10% of acute myeloid leukemia (AML) cases with distinct clinical urgency due to rapid progression and life-threatening coagulopathy [2, 3]. The gene discussed is PML; the disease is acute promyelocytic leukemia.